Skip to main content

Table 4 Assessment of circulating angiogenesis modulating proteins as therapy activity predictors

From: Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

   Treatment failure Objective response or TTF > 4monts Healthy controls
FGF2 (pg/ml) N 5 7 8
  median 3.4 1.8 0.8
  range (1.9-23.7) (0.4-14.8) (0.2-2.3)
  p-value    0.02*
IL8 (pg/ml) N 5 7 8
  median 27.2 5.8 5.8
  range (12.2-61.9) (2.8-18.9) (1.1-7.5)
  p-value    0.006**
TSP-1 (ng/ml) N 5 7 8
  median 125.1 69.6 67.3
  range (85.1-328.4) (24-452) (9-710.1)
  p-value    0.047
VEGF (pg/ml) N 5 7 10
  median 1552 428,6 2094
  range (804.3-2785) (252.4-3116) (1122-2387)
  p-value    0.074
VEGFR-2 (pg/ml) N 5 7 8
  median 13680 13275 12328
  range (8945-16465) (7455-18065) (8235-17615)
  p-value    0.657